Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

OGN

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
23/12/202422:01Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
19/12/202423:30Business WireOrganon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
16/12/202423:30Business WireFDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
07/12/202408:15Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
05/11/202423:40Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
05/11/202423:29Business WireUpdate on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
01/11/202423:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
31/10/202423:40Business Wire米国FDAが、PROLIA/XGEVA(デノスマブ)のバイオシミラー候補HLX14の生物学的製剤承認申請(BLA)を受理NYSE:OGNOrganon and Co
31/10/202423:39Business WireUS-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)NYSE:OGNOrganon and Co
31/10/202423:39Business Wire美國FDA接受PROLIA/XGEVA(地諾單抗)生物學名藥候選藥物HLX14的生物製品授權申請(BLA)NYSE:OGNOrganon and Co
31/10/202423:00Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
31/10/202422:30Business WireOrganon Reports Results for the Third Quarter Ended September 30, 2024NYSE:OGNOrganon and Co
31/10/202415:02Business WireLa FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
30/10/202421:00Business WireUS FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
30/10/202403:22Business WireOrganon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
30/10/202403:22Business Wireオルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®(タピナロフ)クリーム1%を取得NYSE:OGNOrganon and Co
30/10/202403:22Business WireOrganon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %NYSE:OGNOrganon and Co
29/10/202400:25Business WireOrganon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
29/10/202400:25GlobeNewswire Inc.Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
09/10/202422:30Business WireOrganon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024NYSE:OGNOrganon and Co
08/10/202423:01PR Newswire (Canada)Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established BrandsNYSE:OGNOrganon and Co
08/10/202423:01PR Newswire (Canada)Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établiesNYSE:OGNOrganon and Co
01/10/202405:26Business Wireパージェタ(Perjeta®)(ペルツズマブ)バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成NYSE:OGNOrganon and Co
01/10/202402:17Business WirePrimärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreichtNYSE:OGNOrganon and Co
01/10/202401:59Business WireCritères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)NYSE:OGNOrganon and Co
30/09/202420:00Business WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11NYSE:OGNOrganon and Co
26/09/202423:50PR Newswire (Canada)Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in CanadaNYSE:OGNOrganon and Co
26/09/202423:49PR Newswire (Canada)Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au CanadaNYSE:OGNOrganon and Co
24/09/202406:21Edgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
20/09/202404:30Business WireオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®(タピナロフ)クリーム1%を取得NYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN